Novel all-in-one vaccine developed to tackle future coronavirus threats
6 July 2022
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
MRC HIU scientists in Horizon Prize winning team
7 June 2022
Alain Townsend, Tiong Kit Tan and Pramila Rijal among those awarded the Chemistry Biology Interface Division Horizon Prize by the Royal Society of Chemistry.
DNA breakthrough could help identify why some people are more affected by Covid-19
10 June 2021
Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.
Interferon-b trial shows positive results
16 November 2020
A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients. MRC HIU's Professor Ling-Pei Ho is one of the main co-authors on the paper.
Persistent immune memory of COVID-19 found in recovered patient T cells
4 September 2020
New Nature Immunology paper finds strong T cell responses in recovered COVID-19 patients
Uncovering immune responses in COVID-19 patients
7 July 2020
A new study finds T cell immune response variation in recovered COVID-19 patients, including epitopes potentially important for vaccine design.
MRC WIMM researchers part of ground-breaking new study into long-term health impacts of coronavirus
6 July 2020
A major UK research study into the long-term health impacts of COVID-19 on hospitalised patients has been launched.
Oxford-Sri Lanka study to compare COVID-19 immune response
9 June 2020
The study builds on a successful collaboration and will compare T cell and antibody responses to uncover the role of ‘background’ immunity to virus strains already in circulation, including infections with similar coronaviruses.